In conclusion, STAT3 inhibition by GPB730 enhances the antitumoral activity of anti-CTLA-4 in a prostate cancer mouse model, possibly by blocking STAT3 mediated resistance mechanisms such as Tregs in the immunosuppressive environment. This evidence concerns the gene STAT3 and prostate cancer.